232 related articles for article (PubMed ID: 34655168)
1. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
Shen M; Zhang J; Tang R; Wang Y; Zhan X; Fan S; Huang Z; Zhong Y; Li X
Cancer Med; 2022 Jun; 11(11):2173-2183. PubMed ID: 34655168
[TBL] [Abstract][Full Text] [Related]
2. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
3. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
Liu A; Yu H; Hou R; Zhu Z; Zhuang JL; Bao L; Li Z; Liu L; Hua L; Ma Y; Gao D; Jin A; Suo X; Yang W; Bai Y; Fu R; Zheng D; Chen W
Cancer Med; 2024 May; 13(9):e7177. PubMed ID: 38686615
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma].
Chen R; Xue LG; Zhou H; Jia T; Cai ZM; Zhu YX; Miao L; Wei JF; Zhao LD; Mao JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):483-492. PubMed ID: 38660856
[TBL] [Abstract][Full Text] [Related]
5. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Dimopoulos MA; Grosicki S; Jędrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
Eur J Cancer; 2019 Jan; 106():89-98. PubMed ID: 30471652
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Dimopoulos MA; Špička I; Quach H; Oriol A; Hájek R; Garg M; Beksac M; Bringhen S; Katodritou E; Chng WJ; Leleu X; Iida S; Mateos MV; Morgan G; Vorog A; Labotka R; Wang B; Palumbo A; Lonial S;
J Clin Oncol; 2020 Dec; 38(34):4030-4041. PubMed ID: 33021870
[TBL] [Abstract][Full Text] [Related]
7. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
8. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Rajkumar SV; Richardson PG
Leukemia; 2019 Jul; 33(7):1736-1746. PubMed ID: 30696949
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
[TBL] [Abstract][Full Text] [Related]
10. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].
Wang J; Shang JJ; Jin S; Yao Y; Yan Z; Wu DP; Fu CC
Zhonghua Nei Ke Za Zhi; 2022 Jan; 61(1):95-98. PubMed ID: 34979777
[TBL] [Abstract][Full Text] [Related]
12. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
Ludwig H; Poenisch W; Knop S; Egle A; Schreder M; Lechner D; Hajek R; Gunsilius E; Krenosz KJ; Petzer A; Weisel K; Niederwieser D; Einsele H; Willenbacher W; Melchardt T; Greil R; Zojer N
Br J Cancer; 2019 Oct; 121(9):751-757. PubMed ID: 31558804
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Manda S; Yimer HA; Noga SJ; Girnius S; Yasenchak CA; Charu V; Lyons R; Aiello J; Bogard K; Ferrari RH; Cherepanov D; Demers B; Lu V; Whidden P; Kambhampati S; Birhiray RE; Jhangiani HS; Boccia R; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e910-e925. PubMed ID: 32912820
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Kumar SK; Grzasko N; Delimpasi S; Jedrzejczak WW; Grosicki S; Kyrtsonis MC; Spencer A; Gupta N; Teng Z; Byrne C; Labotka R; Dimopoulos MA
Br J Haematol; 2019 Feb; 184(4):536-546. PubMed ID: 30460684
[TBL] [Abstract][Full Text] [Related]
15. The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.
Chen W; Liu A; Li L
Adv Ther; 2023 Feb; 40(2):705-717. PubMed ID: 36463561
[TBL] [Abstract][Full Text] [Related]
16. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.
Goldschmidt H; Dimopoulos MA; Rajkumar SV; Weisel KC; Moreau P; Chng WJ; Mikala G; Cavo M; Ramasamy K; Suryanarayan K; Teng Z; Labotka R; Mateos MV
Leukemia; 2020 Nov; 34(11):3019-3027. PubMed ID: 32327729
[TBL] [Abstract][Full Text] [Related]
17. Clinical study on ixazomib in the treatment of multiple myeloma.
He Y; Zhang K; Zou L; Chen S; Jiang D; Hu J; Zhu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 45(3):322-327. PubMed ID: 32386025
[TBL] [Abstract][Full Text] [Related]
18. Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China.
Ding K; Yu H; Shao YY; Li LY; Wang CM; Song J; Li LJ; Fu R
Cancer Manag Res; 2020; 12():8935-8941. PubMed ID: 33061589
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
20. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
